| Literature DB >> 26408164 |
Tiziana Rubino1, Erica Zamberletti1,2, Daniela Parolaro3,4.
Abstract
Preclinical and clinical data fully support the involvement of the endocannabinoid system in the etiopathogenesis of several mental diseases. In this review we will briefly summarize the most common alterations in the endocannabinoid system, in terms of cannabinoid receptors and endocannabinoid levels, present in mood disorders (anxiety, posttraumatic stress disorder, depression, bipolar disorder, and suicidality) as well as psychosis (schizophrenia) and autism. The arising picture for each pathology is not always straightforward; however, both animal and human studies seem to suggest that pharmacological modulation of this system might represent a novel approach for treatment.Entities:
Keywords: Autism; Bipolar disorder and suicidality; Depression; Endocannabinoid system anxiety; Posttraumatic stress disorder; Schizophrenia
Mesh：
Substances：
Year: 2015 PMID： 26408164 DOI： 10.1007/978-3-319-20825-1_9
Source DB: PubMed Journal: Handb Exp Pharmacol ISSN： 0171-2004